This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0% and 15.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Actinium (ATNM) Up on Commercialization Deal With Immedica
by Zacks Equity Research
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Is Apria (APR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apria (APR) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Surging Earnings Estimates Signal Good News for Actinium (ATNM)
by Zacks Equity Research
Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.40, moving -1.04% from the previous trading session.
Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.11, marking a +0.63% move from the previous day.
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.35, marking a +0.78% move from the previous day.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed at $12.01 in the latest trading session, marking a +0.5% move from the prior day.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.82, marking a +0.34% move from the previous day.
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $9.18, moving -1.71% from the previous trading session.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season?
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
by Zacks Equity Research
United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?